Literature DB >> 20111912

The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.

Ritsuro Suzuki1, Shigeki Ohtake, Jin Takeuchi, Masami Nagai, Yoshihisa Kodera, Motohiro Hamaguchi, Shuichi Miyawaki, Takahiro Karasuno, Shigetaka Shimodaira, Ryuzo Ohno, Shigeo Nakamura, Tomoki Naoe.   

Abstract

Immunological phenotyping of acute leukemia have provided enormous and important information for the classification and lineage determination of leukemia. Forty-nine patients with CD7(+) CD56(+) acute myeloid leukemia (AML) were analyzed. There were 17 patients of M0, which corresponded to myeloid/NK cell precursor acute leukemia, and 32 patients of AML other than M0 (9 each for M1 and M2, one for M3, 3 for M4, 4 for M5 and 6 for M7). Age distribution was similar between these two groups, but CD7(+) CD56(+) M0 showed significant male predominance than CD7(+) CD56(+) M1-M7 (M:F = 15:2 vs. 15:17, P = 0.006). The disease localization and the hematological manifestations were different, showing fewer white blood cell counts and circulating leukemic blasts, less anemia, less thrombocytopenia and more frequent extramedullary involvement in M0 group. The prognosis was poor in both groups, and there was no statistical difference. These findings suggest that extramedullary involvement of myeloid/NK cell precursor acute leukemia is not directly derived from the presence of CD7 and CD56 antigens on leukemic cells. The poor prognosis of CD7(+) CD56(+) M1-M7 suggests that this phenotype may act as a prognostic factor for AML, but this should be confirmed in further studies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20111912     DOI: 10.1007/s12185-010-0492-1

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  36 in total

Review 1.  Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy.

Authors:  C D Jennings; K A Foon
Journal:  Blood       Date:  1997-10-15       Impact factor: 22.113

2.  Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.

Authors:  R Suzuki; Y Kagami; K Takeuchi; M Kami; M Okamoto; R Ichinohasama; N Mori; M Kojima; T Yoshino; H Yamabe; M Shiota; S Mori; M Ogura; N Hamajima; M Seto; T Suchi; Y Morishima; S Nakamura
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

3.  Prognostic significance of CD56 antigen expression in acute myeloid leukemia.

Authors:  Eros Di Bona; Roberto Sartori; Renato Zambello; Nicola Guercini; Domenico Madeo; Francesco Rodeghiero
Journal:  Haematologica       Date:  2002-03       Impact factor: 9.941

4.  Acute myeloid leukemia with hypergranular cytoplasm: a differential diagnosis of acute promyelocytic leukemia.

Authors:  F Girodon; P M Carli; B Favre; L Mannone; S Houssaye; F Mugneret; O Casasnovas; M Maynadié
Journal:  Leuk Res       Date:  2000-11       Impact factor: 3.156

Review 5.  Extranodal NK/T-cell lymphoma: diagnosis and treatment cues.

Authors:  Ritsuro Suzuki; Kengo Takeuchi; Koichi Ohshima; Shigeo Nakamura
Journal:  Hematol Oncol       Date:  2008-06       Impact factor: 5.271

6.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1991-07       Impact factor: 6.998

7.  Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group.

Authors:  K Bradstock; J Matthews; E Benson; F Page; J Bishop
Journal:  Blood       Date:  1994-08-15       Impact factor: 22.113

Review 8.  Progress in understanding and managing natural killer-cell malignancies.

Authors:  Kazuo Oshimi
Journal:  Br J Haematol       Date:  2007-10-03       Impact factor: 6.998

9.  Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.

Authors:  Shigeki Ito; Yoji Ishida; Tatsuo Oyake; Mamiko Satoh; Yusei Aoki; Shugo Kowata; Toshiyuki Uchiyama; Sanae Enomoto; Takeshi Sugawara; Hideharu Numaoka; Keijiro Suzuki; Kazunori Murai
Journal:  Leuk Lymphoma       Date:  2004-09

10.  Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1976-08       Impact factor: 6.998

View more
  5 in total

1.  Erythroblastic sarcoma presenting as bilateral ovarian masses in an infant with pure erythroid leukemia.

Authors:  Huan-You Wang; Lily Jun-shen Huang; Zhaoli Liu; Rolando Garcia; Shiyong Li; Carlos A Galliani
Journal:  Hum Pathol       Date:  2011-01-15       Impact factor: 3.466

2.  Precursor NK cell lymphoblastic leukemia/lymphoma-report of a case with literature review.

Authors:  Sonal Jain; Rajiv Kumar; Abhishek Purohit; Hara Prasad Pati
Journal:  Indian J Hematol Blood Transfus       Date:  2014-03-14       Impact factor: 0.900

Review 3.  A Review of Chimeric Antigen Receptor T-Cell Therapy for Myeloma and Lymphoma.

Authors:  Shebli Atrash; Tamara K Moyo
Journal:  Onco Targets Ther       Date:  2021-03-26       Impact factor: 4.147

4.  MRD abnormal expression predict poor outcomes for refractory or relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.

Authors:  Qi Hao; Xinyue Liu; Yongping Zhang; Dongmei Zhang; Boran Li; Jingbo Wang
Journal:  J Clin Lab Anal       Date:  2021-08-25       Impact factor: 2.352

5.  Acute Megakaryoblastic Leukemia Developing as Donor Cell Leukemia after Umbilical Cord Blood Transplantation.

Authors:  Yoshitaka Adachi; Yohei Yamaguchi; Ken Sagou; Yusuke Yamaga; Nobuaki Fukushima; Kazutaka Ozeki; Akio Kohno
Journal:  Intern Med       Date:  2017-11-20       Impact factor: 1.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.